Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Broccoli extract could slash psychosis risk in At-Risk youth

NCT ID NCT03932136

Prevention Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether sulforaphane, a compound found in broccoli, can prevent psychosis in 300 people at high risk. Participants take either sulforaphane or a placebo daily for a year, then are followed for another year. The main goal is to see if fewer people in the sulforaphane group develop psychosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects meet the criteria of CHR according to the Structured Interview for Prodromal Syndromes (SIPS); 2. Subjects will have no history of being medicated with either antipsychotics or mood stabilizers at their first study visit; 3. Age, within the range of 15 to 45 years; 4. Patients and/or their legal guardians for those younger than 18 year old, can understand and sign informed consent, and agree to take the study interventions and complete all visits and examinations. Exclusion Criteria: 1. A history of schizophrenia or any other psychotic disorders; 2. Severe physical diseases (ie, cardiac and neurologic diseases, brain trauma, liver and kidney diseases, haematopoietic system and immune system dysfunction), or cancer, or other serious complicated diseases; 3. IQ \< 70 is assessed by Wechsler Adult Intelligence Scale-Revised in China, or a specific of developmental delay or intellectual disability; 4. Abnormal laboratory test results with clinical significance which will affect the safety of participants as determined by the investigator; 5. A past and/or current abuse of alcohol, amphetamine or any other psychostimulants; 6. Suicidal ideation, plan, or suicidal behaviour in the last 3 months; 7. Clinically significant allergic reaction to broccoli; 8. Pregnancy or preparing for pregnancy, and/or lactation; 9. Participation in another clinical trial within the last 30 days. 10. Other conditions that make the candidate subject unsuitable for this study as determined by the principal investigators (eg, aggressive behaviour, safety concerns, difficulty to complete the follow-up, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical high risk syndrome of psychosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychotic disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical high risk syndrome of psychosis

Contacts and locations

Locations

  • Guangzhou Psychiatric Hospital

    Guangzhou, Guangdong, 510009, China

  • Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410008, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, 200030, China

  • Shanghai Pudong Nanhui Mental Health Center

    Shanghai, Shanghai Municipality, 201300, China

  • Shanghai Xuhui District Mental Health Center

    Shanghai, Shanghai Municipality, 200032, China

  • Shenzhen Kangning Hospital

    Shenzhen, Shenzhen, 518118, China

  • Suzhou Psychiatric Hospital

    Suzhou, Jiangsu, 201300, China

  • Tianjin Anding Hospital

    Tianjin, Tianjin Municipality, China

  • the First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China